Cost saving must be a re-investment in manufacturing processes, ie, automation. Cost saving should not be sending operations overseas for a "quick fix". The investment of sending surgical instrumentation to China will prove to be a cost increase and is not viewed by the public as being a reinvestment in America. Stryker's transfer of product to China was an answer to Zimmer and was a copycat manuver to apease stock holders. The thought of opening up China as a customer is doubtful.
"The thought of opening up China as a customer is doubtful."
Why would a country with a huge population that puts an incredible amount of stress on the knees via squatting and kneeling and increased standard of living ever represent a potentially viable market for low-cost implants produced in country? Good point.